FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number: 3235-0287										
Estimated average burden										
hours per response:	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SIMARD JOHN					2. Issuer Name and Ticker or Trading Symbol XBiotech Inc. [XBIT]												o of Reportin licable) tor	ng Pe	. ,	
(Last) 5217 WI	(Last) (First) (Middle) 5217 WINNEBAGO LANE							3. Date of Earliest Transaction (Month/Day/Year) 10/04/2021									er (give title v) Chief Execu	utive	Other (s below) Officer	specify
(Street)	Street) AUSTIN TX 78744						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv Line) X	Form filed by One Reporting Person				
(City)	(St	ate) (ž	Zip)													Form filed by More than One Reporting Person				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date				2. Transaction Date (Month/Day/Ye	2A. Deeme Execution I ar) if any (Month/Day		n Date	,	3. Transaction Code (Instr. 8)						15)	Securi Benefi Owned	Amount of ecurities eneficially wned Following		m: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership
							ď		Code	v	Amount		(A) or (D)	Price		Transa	Reported Transaction(s) (Instr. 3 and 4)		tr. 4)	(Instr. 4)
Common Stock				10/04/202	21				S		23,681		D	\$13.0849(1)		3,987,384		D		
Common Stock 10/05/20					1	L			S		14,218		D	\$12.66	641 ⁽¹⁾	3,973,166			D	
Common Stock 10/06/202					1				S		10,714		D	\$12.53	312 ⁽¹⁾	3,962,452			D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3)					ansaction of ode (Instr. Derivativ		ative rities ired osed	Exp (Mo	piration	kercisable and n Date ay/Year)		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Deri Sec (Ins	rice of ivative urity tr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactior (Instr. 4)	,	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	Code V (A) (D)				te ercisab	Expiration le Date		Title	or Number of	ber					

Explanation of Responses:

John Simard, CEO Chairman of XBiotech, Inc., adopted a stock trading plan. He sold total of 48,613 common stock on the open market as part of this 10B5-1 trading plan.

/s/ Queena Han under Power of Attorney for John Simard

10/06/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.